A study has determined that adverse effects leading to treatment discontinuation vary among different blood pressure-lowering drug classes.
Hyperactive signaling pathways of some aggressive blood cancer cells can be tamped down by a previously unrecognized protein complex, ensuring the cancer's survival. If one component of the complex is ...
About The Study: In this study, major adverse cardiovascular event risk varied significantly by medication class, with most protection achieved with sustained treatment with glucagon-like peptide-1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results